Pharmalittle: New ALS drug raises concerns; will Glaxo face bribery charges in the UK?


nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Today, however, we will be daydreaming about a week-long respite. Yes, the time has come to disappear for a few days, although a colleague or two will assume Pharmalittle duties in our absence. And what about you? Any sojourns planned? This is a lovely time to enjoy the great outdoors or take an excursion. Well, whatever you do, have a grand time. But, be safe. See you all soon …

The first new drug for amyotrophic lateral sclerosis, or ALS, in 22 years was approved by U.S. regulators this week, causing excitement but also concerns, ABC News reports. Some physicians worry about the cost for Radicava — about $146,000 per year — as well as misconceptions about how effective the drug will be at fighting the degenerative condition  and that numerous infusions mean many such trips for patients with reduced mobility.



Leave a Reply